Preclinical study demonstrates HemoHIM reduces acetaminophen-induced liver injury in mice and liver cells, suggesting therapeutic value against drug toxicity.
In this study, the hepatoprotective effects of the herbal preparation (HemoHIM) against acetaminopheninduced liver injury were investigated in vitro and in vivo. We investigated the messenger Ribonucleic acid expression of antioxidant factors and proinflammatory cytokines in human hepatocellular carcinoma cells treated with acetaminophen. In vivo study, ICR was divided into five groups (n=10): control, acetaminophen, HemoHIM 250, 500 mg/kg body weight and silymarin 200 mg/kg body weight, respectively. Mice were administrated acetaminophen (350 mg/kg body weight) on d 5 after sample administration. Blood samples were collected for aspartate aminotransferase, alanine transaminase assessment. Liver tissue was determined for glutathione, triglyceride, cholesterol and histopathological features. HemoHIM has significant effects in the treatment groups compared to acetaminophen group.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: